Safety and Efficacy of NMD670 in Adult Patients With Type 1 and Type 2 Charcot-Marie-Tooth Disease
NCT ID: NCT06482437
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
81 participants
INTERVENTIONAL
2024-09-30
2025-11-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NMD670
NMD670
Tablets taken twice daily for 21 days
Placebo
Placebo
Tablets taken twice daily for 21 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NMD670
Tablets taken twice daily for 21 days
Placebo
Tablets taken twice daily for 21 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of CMT type 1 or 2 confirmed by genetic testing.
* Body mass index between 18 and 35 kg/m2, inclusive, at screening, and with a minimum weight of 40 kg
* Contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
* Participant is capable of and has given signed informed consent
Exclusion Criteria
* Participants with laboratory test result abnormalities at screening considered clinically significant by the Investigator.
* Participants who have received treatment with another IMP within 30 days (or 5 half-lives of the medication, whichever is longer) prior to day 1.
* Participants with history of poor compliance with relevant therapy in the opinion of the Investigator.
* Female participants who plan to become pregnant during the study or are currently pregnant or breastfeeding.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NMD Pharma A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Kansas Medical Center, Department of Neurology
Kansas City, Kansas, United States
Mass General Neurology
Boston, Massachusetts, United States
NextGen Precision Health
Columbia, Missouri, United States
Columbia University Medical Center
New York, New York, United States
University of Rochester Neuromuscular Disease Center
Rochester, New York, United States
OSU Department of Neurology Division of Neuromuscular Diseases
Columbus, Ohio, United States
National Neuromuscular research Institute, PLLC
Austin, Texas, United States
Providence Medical Research Center
Spokane, Washington, United States
University Hospitals Leuven, Department of Neurology
Leuven, , Belgium
CHR de la Citadelle- Site Citadelle Neurolgie Boulevard du 12eme de Ligne 1
Liège, , Belgium
Aarhus University Hospital
Aarhus, , Denmark
Rigshospitalet, Department of Neurology
Copenhagen, , Denmark
CHU Marseille, Reference centre for neuromuscular diseases and ALS Department of Neuromuscular Diseases
Marseille, , France
Laboratoire d'Explorations Fonctionnelles, CHU Nantes
Nantes, , France
Centre Hospitalier Universitaire De Nice
Nice, , France
Institut de Myologie Groupe Hospitalier Pitié-Salpêtrière
Paris, , France
Bicêtre University Hospital
Paris, , France
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NMD670-02-0003
Identifier Type: -
Identifier Source: org_study_id